Index S&P 500
P/E -
EPS (ttm) -8.06
Insider Own 8.35%
Shs Outstand 391.00M
Perf Week 3.71%
Market Cap 11.33B
Forward P/E -
EPS next Y -6.71
Insider Trans -0.07%
Shs Float 358.07M
Perf Month 16.21%
Enterprise Value 7.56B
PEG -
EPS next Q -2.63
Inst Own 70.21%
Short Float 19.01%
Perf Quarter 16.78%
Income -3.12B
P/S 5.08
EPS this Y 13.48%
Inst Trans -3.66%
Short Ratio 6.25
Perf Half Y 11.57%
Sales 2.23B
P/B 1.22
EPS next Y 16.48%
ROA -22.31%
Short Interest 68.08M
Perf YTD -30.24%
Book/sh 23.86
P/C 2.52
EPS next 5Y 21.11%
ROE -29.32%
52W High 48.92 -40.70%
Perf Year -32.32%
Cash/sh 11.53
P/FCF -
EPS past 3/5Y - -42.94%
ROIC -31.11%
52W Low 22.28 30.19%
Perf 3Y -84.29%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -43.99% 121.86%
Gross Margin 38.93%
Volatility 3.99% 4.99%
Perf 5Y -82.92%
Dividend TTM -
EV/Sales 3.39
EPS Y/Y TTM -38.95%
Oper. Margin -155.15%
ATR (14) 1.28
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 3.73
Sales Y/Y TTM -56.00%
Profit Margin -139.61%
RSI (14) 62.91
Recom 2.92
Dividend Gr. 3/5Y - -
Current Ratio 3.93
EPS Q/Q -1673.01%
SMA20 11.62%
Beta 1.17
Target Price 35.89
Payout -
Debt/Eq 0.08
Sales Q/Q -45.44%
SMA50 11.05%
Rel Volume 0.88
Prev Close 29.46
Employees 5800
LT Debt/Eq 0.07
Earnings Nov 06 BMO
SMA200 5.37%
Avg Volume 10.89M
Price 29.01
IPO Dec 07, 2018
Option/Short Yes / Yes
EPS/Sales Surpr. 72.79% 10.33%
Trades
Volume 2,034,461
Change -1.54%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-12-25 Initiated
Jefferies
Hold
$30
Mar-13-25 Initiated
Citigroup
Neutral
$40
Feb-18-25 Downgrade
Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade
Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade
Argus
Buy → Hold
Dec-10-24 Resumed
BofA Securities
Underperform
$41
Nov-19-24 Initiated
Berenberg
Hold
$42
Nov-18-24 Upgrade
HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated
Wolfe Research
Underperform
$40
Oct-17-24 Initiated
Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade
Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade
JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade
Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Nov-29-23 Initiated
Canaccord Genuity
Hold
$82
Nov-03-23 Upgrade
HSBC Securities
Reduce → Hold
$89 → $69
Show Previous Ratings
Today 09:05AM
07:00AM
Dec-12-25 10:47AM
09:35AM
09:13AM
02:03PM
Loading…
Dec-11-25 02:03PM
12:50PM
(Pharmaceutical Technology)
07:44AM
Dec-09-25 09:36PM
11:04AM
Dec-08-25 09:30AM
09:30AM
Dec-05-25 02:15PM
Dec-04-25 09:35AM
Dec-03-25 09:01AM
09:40AM
Loading…
Dec-02-25 09:40AM
08:12AM
07:53AM
06:22AM
04:17AM
Dec-01-25 11:03PM
04:46PM
04:45PM
(Investor's Business Daily)
04:38PM
(Investor's Business Daily)
03:36PM
(Investor's Business Daily)
03:05PM
02:57PM
02:19PM
(Investor's Business Daily)
12:35PM
12:24PM
12:23PM
Loading…
12:23PM
12:09PM
11:05AM
10:27AM
(The Wall Street Journal)
09:59AM
09:36AM
07:34AM
Nov-24-25 12:30PM
Nov-23-25 07:00AM
Nov-20-25 08:16PM
(Morningstar Research) -7.53%
+6.08%
09:54AM
(Pharmaceutical Technology)
09:51AM
07:00AM
07:00AM
06:53AM
Nov-19-25 01:35PM
07:00AM
05:33AM
Nov-18-25 07:00AM
Nov-17-25 08:05AM
Nov-13-25 12:14PM
12:39AM
Nov-10-25 10:31PM
09:48AM
09:25AM
Nov-07-25 05:19PM
08:16AM
12:31AM
Nov-06-25 10:30PM
04:40PM
04:14PM
(Investor's Business Daily)
04:03PM
03:29PM
02:16PM
02:15PM
02:11PM
11:58AM
11:16AM
11:14AM
10:36AM
10:10AM
09:47AM
09:37AM
09:37AM
09:37AM
09:33AM
08:15AM
08:09AM
08:08AM
07:39AM
07:29AM
07:13AM
(Associated Press Finance)
07:09AM
(The Wall Street Journal)
07:00AM
05:32AM
04:25AM
Nov-05-25 06:48PM
06:48PM
06:48PM
06:48PM
06:48PM
06:48PM
04:15PM
Nov-04-25 10:21PM
09:45AM
(Associated Press Finance)
08:36AM
Nov-03-25 07:18PM
(Morningstar Research) -8.28%
01:20PM
05:00AM
Oct-31-25 04:25PM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AFEYAN NOUBAR Director Dec 11 '25 Option Exercise 10.90 23,853 259,998 27,777 Dec 15 09:00 AM AFEYAN NOUBAR Director Dec 11 '25 Sale 29.48 23,853 703,306 3,924 Dec 15 09:00 AM Bancel Stephane Chief Executive Officer Dec 11 '25 Option Exercise 10.90 688,073 7,499,996 6,181,970 Dec 15 08:59 AM Flagship Pioneering Inc. Affiliate Dec 11 '25 Proposed Sale 29.49 23,853 703,306 Dec 11 04:30 PM Hussain Abbas Director Dec 09 '25 Sale 27.60 504 13,910 1,515 Dec 11 04:16 PM Hussain Abbas Director Dec 09 '25 Proposed Sale 27.60 504 13,910 Dec 09 10:26 AM Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM